Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine to reactivate antidepressant efficacy in major depressive disorder
ChiCTR2100050335Phase 4Recruiting
- Sponsor
- Beijing Anding Hospital
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of esketamine in major depressive disorder (MDD) (2 arms), sponsored by Beijing Anding Hospital. Primary endpoint: Response rate. Started Apr 2021; status: recruiting.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR2100050335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100050335.